Catalyst Event
Pfizer Inc (PFE) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/29/2026, 12:00:00 AM
Pfizer announced positive topline results on April 29, 2026, from the Phase 3 MagnetisMM-5 study of ELREXFIO, showing a significant improvement in progression-free survival for patients with relapsed or refractory multiple myeloma. Medium importance is estimated based on clinical trial success.
Korean Translation
화이자는 2026년 4월 29일, 재발성 또는 불응성 다발성 골수종 환자를 대상으로 한 엘렉스피오(ELREXFIO)의 3상 임상(MagnetisMM-5)에서 무진행 생존기간의 유의미한 개선을 보인 긍정적인 탑라인 결과를 발표함. 임상 시험 성공에 따른 시장 반응을 고려하여 중요도를 '중간'으로 예상함.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM